Tscan Therapeutics, INC Form 4 insider transactions

Baker Bros. Advisors disclosed a grant of 67,000 stock options to TScan Therapeutics director Dr. Stephen R. Biggar.

Director Keith Woods has been granted 67,000 stock options in TScan Therapeutics as part of a standard equity compensation arrangement.

Director Garry A. Nicholson received a grant of 67,000 stock options with a one-year vesting period, aligning board interests with shareholder value.

Director Katina Dorton was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Barbara Klencke was granted 67,000 stock options in TScan Therapeutics, Inc. as part of a standard equity compensation arrangement.

TScan Therapeutics' Chief Financial Officer, Jason Amello, was granted 350,000 stock options with an exercise price of $1.12 per share.

TScan Therapeutics CEO Gavin MacBeath was granted 1,165,000 stock options with an exercise price of $1.12, vesting over four years.

TScan Therapeutics, Inc. granted 100,000 stock options to its Principal Accounting Officer and Vice President of Finance, Leiden Dworak, with an exercise price of $1.12 per share.

TScan Therapeutics' Chief Medical Officer, Louis Chrystal, acquired 420,000 stock options with an exercise price of $1.12, vesting over four years.

TScan Therapeutics, Inc. has granted its Chief Legal and Strategy Officer, Zoran Zdraveski, 350,000 stock options with an exercise price of $1.12 per share, vesting over four years.

Lynx1 Capital Management LP, a 10% owner and director, increased its beneficial ownership in TScan Therapeutics, Inc. through recent common stock purchases.

TScan Therapeutics, Inc. has granted 67,000 non-qualified stock options to director Dr. Stephen R. Biggar, with an exercise price of $1.45 per share, vesting on the earlier of one year or the next annual meeting, and indirectly benefiting Baker Bros. investment funds.

TScan Therapeutics, Inc. Director Barbara Klencke was granted 67,000 stock options with an exercise price of $1.45, vesting by June 30, 2026, or the next annual meeting.

TScan Therapeutics, Inc. Director Garry A. Nicholson was granted 67,000 stock options with an exercise price of $1.45, vesting by June 30, 2026, or the next annual meeting.

TScan Therapeutics, Inc. Director Keith Woods was granted 67,000 stock options with an exercise price of $1.45, vesting fully by June 30, 2026, or the next annual meeting.

TScan Therapeutics, Inc. Director Katina Dorton was granted 67,000 stock options with an exercise price of $1.45, vesting by June 30, 2026, or the next annual meeting.

TScan Therapeutics, Inc. Director Gabriela Gruia was granted 67,000 stock options with an exercise price of $1.45, vesting upon the earlier of June 30, 2026, or the next annual stockholders' meeting.

Lynx1 Capital Management LP reports acquiring additional shares of TScan Therapeutics, increasing its beneficial ownership.

Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, reports the acquisition of stock options.

Leiden Dworak, Vice President of Finance at TScan Therapeutics, was granted stock options to purchase 46,875 shares of common stock.

TScan Therapeutics' CEO, Gavin MacBeath, has been granted substantial stock options, according to a recent SEC filing.

Jason Amello, CFO of TScan Therapeutics, acquired stock options for 270,000 shares at an exercise price of $3.065 on January 3, 2025.

Chrystal Louis, Chief Medical Officer of TScan Therapeutics, acquired stock options for 400,000 shares on January 3, 2025.

Lynx1 Capital Management, a significant shareholder in TScan Therapeutics, has acquired 7.5 million pre-funded warrants exercisable into common stock, subject to certain ownership limitations.

Lynx1 Capital Management LP has increased its holdings in TScan Therapeutics through multiple purchases of common stock.

Lynx1 Capital Management LP has increased its holdings in TScan Therapeutics through a recent purchase of common stock.

Director Barbara Klencke reports purchasing TScan Therapeutics shares and discloses holdings through a family trust.

Director Barbara Klencke increased her holdings in TScan Therapeutics through open market purchases.

Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, reports the acquisition and disposition of company stock and stock options on August 23, 2024.

Director Keith Woods received a stock option grant for 47,500 shares of TScan Therapeutics, Inc. on June 12, 2024.